US20030129259A1 - Topical lightening compostitions and methods of use - Google Patents
Topical lightening compostitions and methods of use Download PDFInfo
- Publication number
- US20030129259A1 US20030129259A1 US10/034,186 US3418601A US2003129259A1 US 20030129259 A1 US20030129259 A1 US 20030129259A1 US 3418601 A US3418601 A US 3418601A US 2003129259 A1 US2003129259 A1 US 2003129259A1
- Authority
- US
- United States
- Prior art keywords
- composition
- agent
- melanin
- topical
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000000699 topical effect Effects 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims abstract description 16
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 84
- 239000000203 mixture Substances 0.000 claims abstract description 77
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 50
- 239000000284 extract Substances 0.000 claims abstract description 34
- 235000020257 nut milk Nutrition 0.000 claims abstract description 24
- 235000004347 Perilla Nutrition 0.000 claims abstract description 21
- 235000020415 coconut juice Nutrition 0.000 claims abstract description 20
- 210000004209 hair Anatomy 0.000 claims abstract description 17
- 239000012141 concentrate Substances 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000013336 milk Nutrition 0.000 claims abstract description 7
- 239000008267 milk Substances 0.000 claims abstract description 7
- 210000004080 milk Anatomy 0.000 claims abstract description 7
- 244000144725 Amygdalus communis Species 0.000 claims abstract description 6
- 235000011437 Amygdalus communis Nutrition 0.000 claims abstract description 6
- 244000226021 Anacardium occidentale Species 0.000 claims abstract description 6
- 244000068645 Carya illinoensis Species 0.000 claims abstract description 6
- 235000009025 Carya illinoensis Nutrition 0.000 claims abstract description 6
- 240000007049 Juglans regia Species 0.000 claims abstract description 6
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 6
- 235000020224 almond Nutrition 0.000 claims abstract description 6
- 235000020226 cashew nut Nutrition 0.000 claims abstract description 6
- 235000020234 walnut Nutrition 0.000 claims abstract description 6
- 210000003491 skin Anatomy 0.000 claims description 30
- 210000002510 keratinocyte Anatomy 0.000 claims description 18
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 13
- YFTGOBNOJKXZJC-UHFFFAOYSA-N 5,6-dihydroxyindole-2-carboxylic acid Chemical compound OC1=C(O)C=C2NC(C(=O)O)=CC2=C1 YFTGOBNOJKXZJC-UHFFFAOYSA-N 0.000 claims description 12
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 11
- 108010051081 dopachrome isomerase Proteins 0.000 claims description 11
- 208000003351 Melanosis Diseases 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 210000002752 melanocyte Anatomy 0.000 claims description 9
- 208000000069 hyperpigmentation Diseases 0.000 claims description 7
- 230000003810 hyperpigmentation Effects 0.000 claims description 7
- 210000000088 lip Anatomy 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 206010008570 Chloasma Diseases 0.000 claims description 5
- 206010014970 Ephelides Diseases 0.000 claims description 5
- 238000002845 discoloration Methods 0.000 claims description 5
- 238000004383 yellowing Methods 0.000 claims description 5
- 208000012641 Pigmentation disease Diseases 0.000 claims description 4
- 230000019612 pigmentation Effects 0.000 claims description 4
- 210000004761 scalp Anatomy 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 235000020197 coconut milk Nutrition 0.000 claims description 2
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 claims 1
- 244000124853 Perilla frutescens Species 0.000 abstract description 11
- 210000004027 cell Anatomy 0.000 description 21
- 210000002780 melanosome Anatomy 0.000 description 18
- 238000003556 assay Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 244000060011 Cocos nucifera Species 0.000 description 5
- 235000013162 Cocos nucifera Nutrition 0.000 description 5
- 102000003425 Tyrosinase Human genes 0.000 description 5
- 108060008724 Tyrosinase Proteins 0.000 description 5
- 230000008099 melanin synthesis Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000008101 melanin synthesis pathway Effects 0.000 description 4
- 210000000282 nail Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- -1 polysiloxanes Polymers 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- LEEDMQGKBNGPDN-UHFFFAOYSA-N 2-methylnonadecane Chemical compound CCCCCCCCCCCCCCCCCC(C)C LEEDMQGKBNGPDN-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 150000000996 L-ascorbic acids Chemical class 0.000 description 2
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 2
- 102000014171 Milk Proteins Human genes 0.000 description 2
- 108010011756 Milk Proteins Proteins 0.000 description 2
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical compound NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 2
- 244000003892 Vaccinium erythrocarpum Species 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 229940069826 chlorella vulgaris extract Drugs 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229960004337 hydroquinone Drugs 0.000 description 2
- 230000002065 hypopigmenting effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003101 melanogenic effect Effects 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- OQILCOQZDHPEAZ-UHFFFAOYSA-N octyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCCCCCCC OQILCOQZDHPEAZ-UHFFFAOYSA-N 0.000 description 2
- 210000004694 pigment cell Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- WHNCXIBKVUPNHR-UHFFFAOYSA-N 3,4-dihydroxy-1h-indole-2-carboxylic acid Chemical compound C1=CC(O)=C2C(O)=C(C(=O)O)NC2=C1 WHNCXIBKVUPNHR-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 240000002814 Clintonia borealis Species 0.000 description 1
- 235000002937 Clintonia borealis Nutrition 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- XXGJRAFLOAKNCC-AFTCTWSNSA-N I.[2HH].[2H]C[3H] Chemical compound I.[2HH].[2H]C[3H] XXGJRAFLOAKNCC-AFTCTWSNSA-N 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 101000620364 Mus musculus Melanocyte protein PMEL Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 244000258070 Salvia viridis Species 0.000 description 1
- 235000001486 Salvia viridis Nutrition 0.000 description 1
- 241000581682 Sanguisorba Species 0.000 description 1
- 244000173853 Sanguisorba officinalis Species 0.000 description 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 240000000359 Triticum dicoccon Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003793 hair pigmentation Effects 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- 229940078546 isoeicosane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/08—Preparations for bleaching the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9722—Chlorophycota or Chlorophyta [green algae], e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
Definitions
- the present invention relates to the lightening of the skin, hair, nails and/or lips.
- the present invention further relates to compositions and methods for lightening the skin, hair, nails and/or lips.
- Perilla extract is disclosed as a whitening agent in U.S. Pat. Nos. 5,980,904 and Japanese Publications 07025742, 07187989, 10265322, 2001163759, and 2001181173.
- coconut fruit extract is disclosed as a whitening agent in Japanese Patent No. 2896815 B2.
- An extract of spongy mass of coconut tissue is employed in a tanning sunscreen composition in U.S. Pat. No. 5,756,099.
- Skin and hair pigmentation is determined by the level of melanin present in the epidermis and hair fiber, respectively.
- melanin present in, for example, the epidermis: DHI-melanin, DHICA-melanin and pheomelanin.
- the different types of melanin vary in color or shade. DHI-melanin is the darkest and is blackish in color.
- DHICA-melanin is brownish in color.
- Pheomelanin is the lightest and is reddish in color.
- Melanin is synthesized in specialized organelles called melanosomes within pigment-producing cells (melanocytes). Melanocytes respond to stimuli to regulate melanin synthesis.
- a topical composition that provides enhanced levels of lightening, bleaching, hypopigmenting, whitening and/or depigmenting (hereinafter referred to individually and collectively as “lightening” or “lighten”). It would be further desirable to have a topical composition that contains lightening agents that acted to interfere with the conversion of DOPAchrome to DHI-melanin and DHICA-melanin. It would be yet further desirable to have a topical composition that contains lightening agents that act to inhibit or prevent the transfer (uptake) of melanin from the melanocytes to the keratinocytes. It would still yet be further desirable to have methods for lightening the skin, hair, nails and/or lips employing the compositions of the present invention.
- a topical lightening composition comprising a melanin synthesis-regulating agent, and a vehicle.
- a topical lightening composition comprising an extract of perilla leaf and a vehicle.
- a topical lightening composition comprising a lightening agent selected from the group consisting of coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, and combinations of any of the foregoing, and a vehicle.
- a lightening agent selected from the group consisting of coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, and combinations of any of the foregoing, and a vehicle.
- methods for lightening the skin, hair, lips, and/or nails comprising topically applying any one of these compositions.
- FIG. 1 illustrates the results of the melanin uptake assay in the Examples.
- the invention is not limited by any particular characterization of the physiological and/or chemical effects of topical lightening agents.
- the topical lightening agents useful in the compositions and methods of the present invention lighten the skin by regulating melanin production and inhibiting the uptake of melanin in the skin, hair, lips, and/or nails.
- One embodiment of the present invention is the employment of a melanin synthesis-regulating agent individually, or in combination with a melanin uptake-inhibiting agent.
- a melanin synthesis-regulating agent is present in an amount effective to inhibit DCT and/or DHICA polymerase, a superior lightening composition can be attained. It was heretofore unknown in the art that interference in this part of the melanin synthesis pathway could bring about lightening of the skin, hair, lips, and/or nails.
- a flow chart of the melanin synthesis pathway is as follows:
- melanin synthesis-regulating agents include coconut water, coconut milk, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of each of the foregoing, or combinations of any of the foregoing.
- melanin uptake-inhibiting agents include extracts or oils derived from all or parts of the perilla plant, e.g. the leaf, seed, stem, and root.
- a preferred agent is extract of the perilla leaf.
- perilla leaf extract as a lightening agent in a topical lightening composition, either individually or in combination with another lightening agent.
- Perilla leaf extract provides an unexpected enhancement of topical lightening efficacy compared to extracts, concentrates, or oils of other parts of the perilla plant, i.e. the seed, stem and root.
- the perilla leaf extract can provide topical lightening efficacy at a lower amount compared to extracts of other parts of the perilla plant.
- Another embodiment of the present invention is the use of any of the following as a topical lightening agent in a composition: coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, or combinations of any of the foregoing. They can be used as the principal topical lightening agent or in combination with other lightening agents.
- coconut water is preferred.
- a freeze-dried concentrate of coconut water is most preferred.
- coconut water or the concentrate thereof is believed to provide superior lightening efficacy compared to extracts, concentrates, or oils of other parts of the coconut and/or coconut tree, i.e. the fruit, milk, shell, seed, leaf, and bark.
- Topical lightening agents are present in the present composition at a level sufficient to induce the desired effect of lightening.
- the amount will vary depending upon the type of agent and the nature and level of desired effect.
- the lightening agent will typically be present from about 0.001 wt % to about 20 wt %, more preferably from about 0.01 wt % to about 5 wt %, and most preferably from about 0.1 wt % to about 2.5 wt %, based on the total weight of the composition.
- compositions of the present invention preferably include at least one, more preferably at least two, most preferably at least three, of the following ingredients: aloe barbadensis or an extract thereof, hydrolyzed soy protein, n-glucosamine, gamma-aminobutyric acid, a competitive inhibitor of melanocyte stimulating hormone (MSH) (e.g. hexapeptide-2), clintonia borealis (bluebeard lily) or an extract thereof, milk proteins, hydrolyzed milk proteins, sanguisorba officinalis (burnet), a glutathione reductase inhbitor (e.g. wheat germ) or extracts thereof.
- MSH melanocyte stimulating hormone
- compositions of the present invention can be used to effectively lighten skin, hair, lips and nails be topically applying the composition having an effective amount of the topical lightening agent.
- the present compositions should preferably be rubbed onto/into the scalp so that the composition can penetrate into the hair follicles or root shafts and be absorbed into the hair during the melanin production process.
- compositions of the present invention can be applied to treat a variety of skin conditions, including freckles, age spots, dark spots, hyperpigmentation, post-. inflammatory hyperpigmentation, (e.g. post-acne hyperpigmentation), discoloration, melasma, yellowing, and dark circles under the eyes.
- the present compositions may include any vehicle known in the art. Suitable vehicles include, but are not limited to, water; one or more vegetable oils; esters such as octyl palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dicapryl ether and dimethyl isosorbide; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, stearyl alcohol and behenyl alcohol; isoparaffins such as isooctane, isododecane and isohexadecane; silicone oils such as dimethicones and polysiloxanes; hydrocarbon oils such as mineral oil, petrolatum, isoeicosane and polyisobutene; polyols such as propylene glycol, glycerin, butylene glycol, pentylene glycol and hexylene glycol; or combinations thereof.
- Suitable vehicles include, but are not limited to, water; one or
- the present compositions may include additional skin whitening agents known in the art.
- useful agents include the following: hydroquinone, kojic acid, licorice and/or its derivatives, ascorbic acid/ascorbic acid derivatives, arbutin, bearberry, Glycyrrhiza glabra and its derivatives, and Chlorella vulgaris extract.
- Other whitening agents are disclosed in U.S. Pat. No. 5,980,904, which is incorporated by reference herein.
- compositions may include one or more of the following ingredients: anesthetics, anti-allergenics, antifungals, antimicrobials, anti-inflammatories, antiseptics, chelating agents, colorants, emollients, exfollients, film formers, fragrances, humectants, insect repellents, lubricants, moisturizers, pharmaceutical agents, preservatives, skin protectants, skin penetration enhancers, stabilizers, surfactants, thickeners, viscosity modifiers, or vitamins.
- compositions can be made into any suitable product form.
- product forms include, but are not limited to, a cream, lotion, ointment, gel, foam, pomade, aerosol spray, pump spray, a stick, towelette, or patch.
- DOPAchrome Tautomerase (DCT) activity was assayed according to the method disclosed in Chakraborty et al., 1998, Effect of arbutin on melanogenic proteins in human melanocytes, Pigment Cell Res. 11: 206-212. Specifically, ice-cold DOPA (0.5 mg per ml of 0.1 M sodium phosphate buffer, pH 6.8) was mixed with Ag 2 O (30 mg Ag 2 O: 1 mg DOPA) for about 1 minute and filtered through a 0.22 ⁇ m Millipore filter. DCT was assayed spectrophotometrically by adding up to 0.1 ml cell extract to 0.5 ml of a solution of freshly prepared DOPAchrome ( ⁇ 0.5 mg/ml).
- DOPAchrome Tautomerase (DCT) activity was assayed according to the method disclosed in Chakraborty et al., 1998, Effect of arbutin on melanogenic proteins in human melanocytes, Pigment Cell Res. 11: 206-212. Specifically, ice-
- a DHICA polymerase assay was done according to the method disclosed in Chakraborty et al., 1996, Polymerization of 5,6-dihydroxyindole-2-Carboxylic acid to melanin by the pmel17/silver locus protein, Eur. J. Biochem. 236: 180-188. Specifically, the cell extract (0.5 ml, 150-200 ⁇ g protein) was passed through a wheat germ agglutinin column (1 ml bed volume) equilibrated with lysis buffer. The bound material was eluted with 0.5 ml 1M N-acetyl glucosamine, which contains crude DHICA polymerization factor and other melanogenic proteins.
- Confluent cultures of B16 melanocytes produce moderate levels of melanosomes. However, to induce elevated melanosome production in this cell line, semi-confluent (60%) cultures of B16 cells were treated for approximately 36 hours with normal growth medium supplemented with 10 mM ammonium chloride (final conc.). The medium was then aspirated and the hypermelanotic cells were washed (2 ⁇ 2 ml) with distilled water to provide a hypotonic stress to the cells. An aliquot (2 ml) of a hypotonic lysis solution (0.02% NP-40 in water) was added to each plate and the plates were incubated for approximately 5 min at room temperature.
- a hypotonic lysis solution 0.02% NP-40 in water
- the cellular material from three (3) culture plates were pooled in a 15 ml conical tube and centrifuged at approximately (200 ⁇ g) for 5 minutes to remove cellular debris.
- the resulting supernatant containing melanosomes was transferred to a clean 15 ml conical tube and centrifuged (850 ⁇ g) for 20 minutes.
- the resulting pellet containing the isolated melanosomes were resuspended in 1 ml of Phosphate Buffered Saline (PBS) and stored at 4° C. until used.
- PBS Phosphate Buffered Saline
- NHEKs normal human epidermal keratinocytes
- DMEM/KGM-2 the appropriate growth medium
- the cells were treated with different concentations of perilla leaf extract (powder form or aqueous form). The cells were then returned to the incubator for approximately 1.5 hours.
- each well of keratinocytes was treated with the amount of melanosomes isolated from a single plate of B16 cells.
- the 24 well plates of treated keratinocytes were centrifuged for 15 minutes at 1,000 rpm to facilitate the deposition of the melanosomes onto the surface membranes of the keratinocytes. The plates were then returned to the incubator for 1.25 hours.
- the cells in each well of keratinocytes were rinsed (3 ⁇ 1 ml) with PBS, removed from the plate using trypsin/EDTA, washed with PBS.
- the internalized melanin was extracted from the cells according to a modified method of Bessou-Touya, S., et al. (Chimeric human epidermal reconstructs to study the role of melanocytes and keratinocytes in pigmentation and photoprotection. J. Invest. Dermatol., 111:1103-1108, 1998) and quantified spectrophotometrically by determining the melanin-specific absorbance at 405 nm.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
There is provided a topical lightening composition having a melanin synthesis-regulating agent and a vehicle. There is also provided a topical lightening composition having an extract of perilla leaf and a vehicle. There is also provided a topical lightening composition having a lightening agent selected from the group consisting of coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, and any combinations thereof, along with a vehicle. The compositions and methods of the invention are effective to lighten skin, hair, lips, and/or nails.
Description
- 1. Field of the Invention
- The present invention relates to the lightening of the skin, hair, nails and/or lips. The present invention further relates to compositions and methods for lightening the skin, hair, nails and/or lips.
- 2. Description of the Prior Art
- Consumers, particularly those in Asia, have sought to lighten and reduce uneven pigmentation in the skin. Common skin conditions treated include freckles, age spots, dark spots, hyperpigmentation, discoloration, melasma, yellowing, and dark circles under the eyes.
- Numerous substances have been applied to the skin to lighten the skin. Such substances include hydroquinone, kojic acid, licorice and/or its derivatives, ascorbic acid/ascorbic acid derivatives, arbutin, bearberry, Glycyrrhiza glabra and its derivatives, Chlorella vulgaris extract, perilla extract, and coconut fruit extract. Perilla extract is disclosed as a whitening agent in U.S. Pat. Nos. 5,980,904 and Japanese Publications 07025742, 07187989, 10265322, 2001163759, and 2001181173. Coconut fruit extract is disclosed as a whitening agent in Japanese Patent No. 2896815 B2. An extract of spongy mass of coconut tissue is employed in a tanning sunscreen composition in U.S. Pat. No. 5,756,099.
- Skin and hair pigmentation is determined by the level of melanin present in the epidermis and hair fiber, respectively. Three different types of melanin are present in, for example, the epidermis: DHI-melanin, DHICA-melanin and pheomelanin. The different types of melanin vary in color or shade. DHI-melanin is the darkest and is blackish in color. DHICA-melanin is brownish in color. Pheomelanin is the lightest and is reddish in color.
- Melanin is synthesized in specialized organelles called melanosomes within pigment-producing cells (melanocytes). Melanocytes respond to stimuli to regulate melanin synthesis.
- Most conventional topical lightening agents act by interfering with the action of tyrosinase, the enzyme that catalyzes the conversion of the amino acid tyrosine to DOPAquinone. Previously, it has not been known that hypopigmenting could be achieved by inhibiting enzymes “downstream” from tyrosinase in the melanin synthesis pathway. It has now been discovered that the use of a melanin synthesis regulating agent that inhibits DOPAchrome tautomerase and/or DHICA-polymerase results in a composition with superior lightening, especially skin lightening.
- It would be desirable to have a topical composition that provides enhanced levels of lightening, bleaching, hypopigmenting, whitening and/or depigmenting (hereinafter referred to individually and collectively as “lightening” or “lighten”). It would be further desirable to have a topical composition that contains lightening agents that acted to interfere with the conversion of DOPAchrome to DHI-melanin and DHICA-melanin. It would be yet further desirable to have a topical composition that contains lightening agents that act to inhibit or prevent the transfer (uptake) of melanin from the melanocytes to the keratinocytes. It would still yet be further desirable to have methods for lightening the skin, hair, nails and/or lips employing the compositions of the present invention.
- It is an object of the present invention to provide a composition for lightening of the skin.
- It is an object of the present invention to provide a composition to alter/modify melanin synthesis in the skin.
- It is an object of the present invention to provide a composition to inhibit or prevent the uptake of melanin by keratinocytes.
- It is an object of the present invention to provide methods for effecting the foregoing.
- These and other objects and advantages of the present invention are provided by a topical lightening composition comprising a melanin synthesis-regulating agent, and a vehicle. There is also a topical lightening composition comprising an extract of perilla leaf and a vehicle. There is also a topical lightening composition comprising a lightening agent selected from the group consisting of coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, and combinations of any of the foregoing, and a vehicle. There are also methods for lightening the skin, hair, lips, and/or nails comprising topically applying any one of these compositions.
- FIG. 1 illustrates the results of the melanin uptake assay in the Examples.
- It was found surprising and unexpected that there were topical lightening compositions that provided enhanced levels of performance heretofore not possible. It was found possible to enhance lightening by inhibiting enzymes other than tyrosinase, specifically DOPAchrome tautomerase (DCT) and/or 5,6-dihydroxyindole-2-carboxylic acid polymerase (DHICA-polymerase). It was also found possible to enhance lightening by inhibiting and/or preventing the uptake of melanin by keratinocytes in, for example, the epidermis.
- In its broadest aspects, the invention is not limited by any particular characterization of the physiological and/or chemical effects of topical lightening agents. However, the topical lightening agents useful in the compositions and methods of the present invention lighten the skin by regulating melanin production and inhibiting the uptake of melanin in the skin, hair, lips, and/or nails.
- One embodiment of the present invention is the employment of a melanin synthesis-regulating agent individually, or in combination with a melanin uptake-inhibiting agent. When the melanin synthesis-regulating agent is present in an amount effective to inhibit DCT and/or DHICA polymerase, a superior lightening composition can be attained. It was heretofore unknown in the art that interference in this part of the melanin synthesis pathway could bring about lightening of the skin, hair, lips, and/or nails. A flow chart of the melanin synthesis pathway is as follows:
- Moreover, the use of an additional agent that functions to inhibit the transfer (uptake) of melanin from the melanocytes to the keratinocytes further enhances the lightening efficacy of the present invention.
- Examples of melanin synthesis-regulating agents include coconut water, coconut milk, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of each of the foregoing, or combinations of any of the foregoing. Coconut water that has been concentrated, especially by freeze-drying, is most preferred.
- Examples of melanin uptake-inhibiting agents include extracts or oils derived from all or parts of the perilla plant, e.g. the leaf, seed, stem, and root. A preferred agent is extract of the perilla leaf.
- Another embodiment of the present invention is the use of perilla leaf extract as a lightening agent in a topical lightening composition, either individually or in combination with another lightening agent. Perilla leaf extract provides an unexpected enhancement of topical lightening efficacy compared to extracts, concentrates, or oils of other parts of the perilla plant, i.e. the seed, stem and root. In addition to enhanced efficacy, the perilla leaf extract can provide topical lightening efficacy at a lower amount compared to extracts of other parts of the perilla plant.
- Another embodiment of the present invention is the use of any of the following as a topical lightening agent in a composition: coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, or combinations of any of the foregoing. They can be used as the principal topical lightening agent or in combination with other lightening agents. Coconut water is preferred. A freeze-dried concentrate of coconut water is most preferred. Coconut water or the concentrate thereof is believed to provide superior lightening efficacy compared to extracts, concentrates, or oils of other parts of the coconut and/or coconut tree, i.e. the fruit, milk, shell, seed, leaf, and bark.
- Topical lightening agents are present in the present composition at a level sufficient to induce the desired effect of lightening. The amount will vary depending upon the type of agent and the nature and level of desired effect. The lightening agent will typically be present from about 0.001 wt % to about 20 wt %, more preferably from about 0.01 wt % to about 5 wt %, and most preferably from about 0.1 wt % to about 2.5 wt %, based on the total weight of the composition.
- The compositions of the present invention preferably include at least one, more preferably at least two, most preferably at least three, of the following ingredients: aloe barbadensis or an extract thereof, hydrolyzed soy protein, n-glucosamine, gamma-aminobutyric acid, a competitive inhibitor of melanocyte stimulating hormone (MSH) (e.g. hexapeptide-2), clintonia borealis (bluebeard lily) or an extract thereof, milk proteins, hydrolyzed milk proteins, sanguisorba officinalis (burnet), a glutathione reductase inhbitor (e.g. wheat germ) or extracts thereof.
- The compositions of the present invention can be used to effectively lighten skin, hair, lips and nails be topically applying the composition having an effective amount of the topical lightening agent. To lighten the color or shade of hair, the present compositions should preferably be rubbed onto/into the scalp so that the composition can penetrate into the hair follicles or root shafts and be absorbed into the hair during the melanin production process.
- The topical compositions of the present invention can be applied to treat a variety of skin conditions, including freckles, age spots, dark spots, hyperpigmentation, post-. inflammatory hyperpigmentation, (e.g. post-acne hyperpigmentation), discoloration, melasma, yellowing, and dark circles under the eyes.
- The present compositions may include any vehicle known in the art. Suitable vehicles include, but are not limited to, water; one or more vegetable oils; esters such as octyl palmitate, isopropyl myristate and isopropyl palmitate; ethers such as dicapryl ether and dimethyl isosorbide; alcohols such as ethanol and isopropanol; fatty alcohols such as cetyl alcohol, stearyl alcohol and behenyl alcohol; isoparaffins such as isooctane, isododecane and isohexadecane; silicone oils such as dimethicones and polysiloxanes; hydrocarbon oils such as mineral oil, petrolatum, isoeicosane and polyisobutene; polyols such as propylene glycol, glycerin, butylene glycol, pentylene glycol and hexylene glycol; or combinations thereof.
- Further optionally, the present compositions may include additional skin whitening agents known in the art. Examples of useful agents include the following: hydroquinone, kojic acid, licorice and/or its derivatives, ascorbic acid/ascorbic acid derivatives, arbutin, bearberry, Glycyrrhiza glabra and its derivatives, and Chlorella vulgaris extract. Other whitening agents are disclosed in U.S. Pat. No. 5,980,904, which is incorporated by reference herein.
- Further optionally, the present compositions may include one or more of the following ingredients: anesthetics, anti-allergenics, antifungals, antimicrobials, anti-inflammatories, antiseptics, chelating agents, colorants, emollients, exfollients, film formers, fragrances, humectants, insect repellents, lubricants, moisturizers, pharmaceutical agents, preservatives, skin protectants, skin penetration enhancers, stabilizers, surfactants, thickeners, viscosity modifiers, or vitamins.
- The compositions can be made into any suitable product form. Such product forms include, but are not limited to, a cream, lotion, ointment, gel, foam, pomade, aerosol spray, pump spray, a stick, towelette, or patch.
- The effect of coconut water (freeze-dried concentrate) on the melanin synthesis pathway was demonstrated with various assays using mouse melanoma cells from the S91 cell line (hereinafter “cells”). The cells were cultured in 1:1 mixture of Ham F10+10% horse serum and DMEM+10% fetal bovine serum. All cell experiments were conducted in a humidified, 5% CO2 incubator at 37 degrees C. Cells were treated with 0.02% and 0.05% w/v concentrations of coconut water (freeze-dried concentrate) respectively for 24 hours. Cell extracts were attained at 24 hours, and the following assays were performed: DOPAchrome Tautomerase (Example 1) and DHICA Polymerase (Example 2).
- DOPAchrome Tautomerase (DCT) activity was assayed according to the method disclosed in Chakraborty et al., 1998, Effect of arbutin on melanogenic proteins in human melanocytes, Pigment Cell Res. 11: 206-212. Specifically, ice-cold DOPA (0.5 mg per ml of 0.1 M sodium phosphate buffer, pH 6.8) was mixed with Ag 2O (30 mg Ag2O: 1 mg DOPA) for about 1 minute and filtered through a 0.22 μm Millipore filter. DCT was assayed spectrophotometrically by adding up to 0.1 ml cell extract to 0.5 ml of a solution of freshly prepared DOPAchrome (˜0.5 mg/ml). Reactions were carried out at room temperature in plastic cuvettes, and the disappearance of absorption at 475 nm was followed. Phenylthiourea (1 mM) was added to the reaction mixture, because the presence of tyrosinase in the cell extract can interfere with the assay. The percentage conversion of DOPAchrome was calculated per mg of protein extract and normalized against the control. It was demonstrated that 0.02% wt./vol. coconut water (freeze-dried) provided an average decrease in DOPAchrome conversion of 50% (42/58) as compared to the control.
- A DHICA polymerase assay was done according to the method disclosed in Chakraborty et al., 1996, Polymerization of 5,6-dihydroxyindole-2-Carboxylic acid to melanin by the pmel17/silver locus protein, Eur. J. Biochem. 236: 180-188. Specifically, the cell extract (0.5 ml, 150-200 μg protein) was passed through a wheat germ agglutinin column (1 ml bed volume) equilibrated with lysis buffer. The bound material was eluted with 0.5 ml 1M N-acetyl glucosamine, which contains crude DHICA polymerization factor and other melanogenic proteins. A reaction mixture of 0.5 ml containing either the enzyme preparation to be measured (20 μg protein from wheat germ agglutinin eluates) or the appropriate buffer blank, DHICA (0.5 mM), and 100 mM sodium phosphate buffer, pH 7.0. Phenylthiourea was also included to inhibit endogenous tyrosinase activity in the preparation.
- Spectrophotomeric reading of the absorbance of the reaction mixture was taken at T=0 and T=4 hours time points at 400 nm. DHICA-melanin, but not DHICA itself, has been shown to absorb light at these wavelengths (Orlow et al., 1992, Synthesis and characterization of melanins from dihydroxyindole-2-carboxylic acid and dihydroxyndole, Pigment Cell Res. 5: 113-121). An increase in absorbance over that seen in blank tubes was defined as specific DHICA polymerization factor activity. It was demonstrated that 0.02% wt./vol. coconut water (freeze-dried) provided an average of 52.5% (55%/50%) decrease in DOPAchrome conversion as compared to the control. At 0.05% wt./vol. coconut water (freeze-dried) provided an average decrease of 75% (74/76) in DOPAchrome conversion as compared to the control.
- Melanosome Isolation
- Confluent cultures of B16 melanocytes produce moderate levels of melanosomes. However, to induce elevated melanosome production in this cell line, semi-confluent (60%) cultures of B16 cells were treated for approximately 36 hours with normal growth medium supplemented with 10 mM ammonium chloride (final conc.). The medium was then aspirated and the hypermelanotic cells were washed (2×2 ml) with distilled water to provide a hypotonic stress to the cells. An aliquot (2 ml) of a hypotonic lysis solution (0.02% NP-40 in water) was added to each plate and the plates were incubated for approximately 5 min at room temperature. Following verification of cell lysis using light microscopy, the cellular material from three (3) culture plates were pooled in a 15 ml conical tube and centrifuged at approximately (200×g) for 5 minutes to remove cellular debris. The resulting supernatant containing melanosomes was transferred to a clean 15 ml conical tube and centrifuged (850×g) for 20 minutes. The resulting pellet containing the isolated melanosomes were resuspended in 1 ml of Phosphate Buffered Saline (PBS) and stored at 4° C. until used.
- Treatment of Keratinocytes with Melanosomes
- The normal human epidermal keratinocytes (NHEKs) (available from Clonetics, Inc.) were plated in the wells of 24-well plates at a density of 200,000 cells/well. Approximately 24 hours later, the growth medium was replaced with 1 ml of the appropriate growth medium (i.e., DMEM/KGM-2) containing the melanosome preparation with or without additional treatment conditions. The cells were treated with different concentations of perilla leaf extract (powder form or aqueous form). The cells were then returned to the incubator for approximately 1.5 hours. For these studies, each well of keratinocytes was treated with the amount of melanosomes isolated from a single plate of B16 cells.
- In some experiments, the 24 well plates of treated keratinocytes were centrifuged for 15 minutes at 1,000 rpm to facilitate the deposition of the melanosomes onto the surface membranes of the keratinocytes. The plates were then returned to the incubator for 1.25 hours.
- Analysis of Melanosome Uptake
- For analysis, the cells in each well of keratinocytes were rinsed (3×1 ml) with PBS, removed from the plate using trypsin/EDTA, washed with PBS. To analyze the uptake of melanosomes by the keratinocytes, the internalized melanin was extracted from the cells according to a modified method of Bessou-Touya, S., et al. (Chimeric human epidermal reconstructs to study the role of melanocytes and keratinocytes in pigmentation and photoprotection. J. Invest. Dermatol., 111:1103-1108, 1998) and quantified spectrophotometrically by determining the melanin-specific absorbance at 405 nm.
- Results
- Melanocytes synthesize melanin and deposits onto melanosomes. Visual manifestation of skin color is due to presence of melanin/melanosomes in keratinocytes. Melanosomes are taken up by keratinocytes and the rate of uptake, retention and processing of melanosomes in the keratinocytes is a key determinant of skin color. Thus, the internalized melanin value reflects the amount of melanin/melanosome uptake and retention by the keratinocytes. Thus, lower internalized melanin values, particularly internalized melanin values that are less than the control with melanin, indicate that melanin uptake by the keratinocytes has been inhibited. As illustrated in FIG. 1, internalized melanin values for perilla leaf extract were lower than internalized melanin values of the control with melanin.
- It should be understood that the foregoing description is only illustrative of the present invention. Various alternatives and modifications can be devised by those skilled in the art without departing from the invention. Accordingly, the present invention is intended to embrace all such alternatives, modifications and variances which fall within the scope of the appended claims.
Claims (30)
1. A composition, comprising:
a) a topical lightening agent in an amount effective to inhibit DOPAchrome tautomerase, DHICA polymerase, or both; and
b) a vehicle.
2. The composition of claim 1 , wherein the topical lightening agent has a melanin synthesis-regulating agent.
3. The composition of claim 2 , wherein the melanin synthesis-regulating agent is selected from the group consisting of coconut water, palm water, concentrates of the foregoing, and any combinations thereof.
4. The composition of claim 2 , wherein the melanin synthesis-regulating agent is a concentrate of coconut water.
5. The composition of claim 2 , wherein the melanin synthesis-regulating agent is selected from the group consisting of coconut milk, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, and any combinations thereof.
6. The composition of claim 2 , wherein the topical lightening agent further has a melanin uptake-inhibiting agent in an amount effective to inhibit the transfer of melanin from melanocytes to keratinocytes.
7. The composition of claim 6 , wherein the melanin uptake-inhibiting agent is an extract of perilla.
8. The composition of claim 6 , wherein the melanin uptake-inhibiting agent is an extract selected from the group consisting of perilla leaf, perilla seed, perilla stem, and perilla root.
9. The composition of claim 6 , wherein the melanin synthesis-regulating agent is a concentrate of coconut water and the melanin uptake-inhibiting agent is a perilla leaf extract.
10. The composition of claim 1 , wherein the topical lightening agent is present in an amount about 0.001 to about 20 wt % based on the total weight of the composition.
11. The composition of claim 1 , wherein the topical lightening agent is present in an amount about 0.01 to about 5 wt % based on the total weight of the composition.
12. The composition of claim 1 , wherein the topical lightening agent is present in an amount about 0.1 to about 2.5 wt % based on the total weight of the composition.
13. The composition of claim 1 , wherein the composition is in a product form selected from the group consisting of a cream, a lotion, an ointment, a gel, a foam, a pomade, an aerosol spray, a pump spray, a stick, a towelette, and a patch.
14. A method of lightening skin, hair, lips, and/or nails, comprising: applying topically to the skin, scalp, hair, lips, and/or nails the composition according to claim 1 .
15. The method of claim 14 , wherein the composition is topically applied to treat a skin condition selected from the group consisting of freckles, age spots, dark spots, hyperpigmentation, post-inflammatory hyperpigmentation, discoloration, melasma, yellowing, dark circles under the eyes, and any combinations thereof.
16. A topical composition, comprising:
a) an extract of perilla leaf and
b) a vehicle.
17. The composition of claim 16 , wherein the perilla leaf extract is present in an amount effective to inhibit the uptake of melanin by keratinocytes in the skin.
18. The composition of claim 16 , wherein the perilla leaf extract is present in an amount about 0.001 to about 20 wt % based on the total weight of the composition.
19. The composition of claim 16 , wherein the perilla leaf extract is present in an amount about 0.01 to about 5 wt % based on the total weight of the composition.
20. The composition of claim 16 , wherein the perilla leaf extract is present in an amount about 0.1 to about 2.5 wt % based on the total weight of the composition.
21. The composition according to claim 16 , wherein the composition is in a product form selected from the group consisting of a cream, a lotion, an ointment, a gel, a foam, a pomade, an aerosol spray, a pump spray, a stick, a towelette, and a patch.
22. A method of lightening skin, hair, lips, and/or nails, comprising: applying topically to the skin, scalp, hair and/or nails the composition according to claim 17 .
23. The method of claim 22 , wherein the composition is topically applied to treat a skin condition selected from the group consisting of freckles, age spots, dark spots, hyperpigmentation, post-inflammatory pigmentation, discoloration, yellowing, melasma, dark circles under the eyes, and any combinations thereof.
24. A composition, comprising:
a) a topical lightening agent selected from the group consisting of coconut water, palm water, palm nut milk, pecan nut milk, almond nut milk, cashew nut milk, walnut nut milk, concentrates of the foregoing, and any combinations thereof; and
c) a vehicle,
wherein the topical lightening agent is present in an amount effective to inhibit DOPAchrome tautomerase, DHICA polymerase or both.
25. The composition of claim 24 , wherein the topical lightening agent is coconut water or a concentrate thereof.
26. The composition of claim 26 , wherein the topical lightening agent is present in an amount about 0.001 to about 20 wt % based on the total weight of the composition.
27. The composition of claim 26 , wherein the topical lightening agent is present in an amount about 0.01 to about 5 wt % based on the total weight of the composition.
28. The composition of claim 26 , wherein the topical lightening agent is present in an amount about 0.1 to about 2.5 wt % based on the total weight of the composition.
29. A method of lightening skin, hair, lips, and/or nails comprising: applying topically to the skin, scalp, lips, hair, and/or nails the composition according to claim 24 .
30. The method of claim 29 , wherein the composition is topically applied to treat a skin condition selected from the group consisting of freckles, age spots, dark spots, hyperpigmentation, post-inflammatory pigmentation, discoloration, yellowing, melasma, dark circles under the eyes, and any combinations thereof.
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/034,186 US20030129259A1 (en) | 2001-12-28 | 2001-12-28 | Topical lightening compostitions and methods of use |
| CA002411222A CA2411222C (en) | 2001-12-28 | 2002-11-06 | Topical lightening compositions and methods of use |
| JP2002348249A JP4601898B2 (en) | 2001-12-28 | 2002-11-29 | Topical lightening composition and method of use |
| MXPA02011912A MXPA02011912A (en) | 2001-12-28 | 2002-12-02 | Lightening compositions and methods of use. |
| US10/319,781 US7014844B2 (en) | 2001-12-28 | 2002-12-13 | Lightening compositions and methods of use |
| EP02028448A EP1325738B1 (en) | 2001-12-28 | 2002-12-19 | Non therapeutical methods and medical uses for depigmenting the skin |
| DE60218125T DE60218125T2 (en) | 2001-12-28 | 2002-12-19 | Non-therapeutic method as well as therapeutic applications for skin depigmentation |
| PL357931A PL211313B1 (en) | 2001-12-28 | 2002-12-20 | Brightening compositions for local application and method of using them |
| CNB021598061A CN1293862C (en) | 2001-12-28 | 2002-12-27 | Loal color-lightening compound and its application method |
| US11/215,874 US7544351B2 (en) | 2001-12-28 | 2005-08-31 | Topical lightening compositions and methods of use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/034,186 US20030129259A1 (en) | 2001-12-28 | 2001-12-28 | Topical lightening compostitions and methods of use |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/319,781 Continuation-In-Part US7014844B2 (en) | 2001-12-28 | 2002-12-13 | Lightening compositions and methods of use |
| US11/215,874 Continuation US7544351B2 (en) | 2001-12-28 | 2005-08-31 | Topical lightening compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20030129259A1 true US20030129259A1 (en) | 2003-07-10 |
Family
ID=21874835
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/034,186 Abandoned US20030129259A1 (en) | 2001-12-28 | 2001-12-28 | Topical lightening compostitions and methods of use |
| US10/319,781 Expired - Fee Related US7014844B2 (en) | 2001-12-28 | 2002-12-13 | Lightening compositions and methods of use |
| US11/215,874 Expired - Fee Related US7544351B2 (en) | 2001-12-28 | 2005-08-31 | Topical lightening compositions and methods of use |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/319,781 Expired - Fee Related US7014844B2 (en) | 2001-12-28 | 2002-12-13 | Lightening compositions and methods of use |
| US11/215,874 Expired - Fee Related US7544351B2 (en) | 2001-12-28 | 2005-08-31 | Topical lightening compositions and methods of use |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20030129259A1 (en) |
| EP (1) | EP1325738B1 (en) |
| JP (1) | JP4601898B2 (en) |
| CN (1) | CN1293862C (en) |
| CA (1) | CA2411222C (en) |
| DE (1) | DE60218125T2 (en) |
| MX (1) | MXPA02011912A (en) |
| PL (1) | PL211313B1 (en) |
Cited By (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060198809A1 (en) * | 2005-03-04 | 2006-09-07 | Woodridge Labs, Inc. | Gamma-amino butyric acid composition |
| US20100158829A1 (en) * | 2008-12-24 | 2010-06-24 | Conopco, Inc., D/B/A Unilever | Method and Composition for Color Modulation |
| US20120156144A1 (en) * | 2002-10-25 | 2012-06-21 | Foamix | Foamable Compositions, Kits and Methods for Hyperhidrosis |
| US9023327B2 (en) * | 2012-08-30 | 2015-05-05 | Avon Products, Inc. | DICKKOPF-1 expression modulating compositions and uses thereof |
| US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
| US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
| US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
| US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
| US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US11357792B2 (en) | 2017-09-15 | 2022-06-14 | Dyvve Biosciences, Inc. | Method of administration and treatment |
| US11491225B2 (en) | 2014-12-23 | 2022-11-08 | Dyve Biosciences, Inc. | Transdermal carrier |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| US20030129259A1 (en) * | 2001-12-28 | 2003-07-10 | Avon Products, Inc. | Topical lightening compostitions and methods of use |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
| US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| US20040126351A1 (en) * | 2002-12-26 | 2004-07-01 | Avon Products, Inc. | Topical composition having natural skin anti-irritant ingredient and method of use |
| US7575739B2 (en) * | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US20080069779A1 (en) * | 2003-08-04 | 2008-03-20 | Foamix Ltd. | Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| AU2004296694C1 (en) | 2003-12-15 | 2011-05-19 | Kuraray Co., Ltd. | External preparations for skin |
| JP5311760B2 (en) * | 2007-05-25 | 2013-10-09 | 雪印メグミルク株式会社 | Whitening agent |
| US8518376B2 (en) | 2007-12-07 | 2013-08-27 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| AU2009205314A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| FR2926720B1 (en) * | 2008-01-24 | 2011-09-09 | Jean Noel Thorel | COSMETIC COMPOSITION FOR BLOCKING SKIN PIGMENTATION INDUCED BY UV RADIATION |
| ES2327201B1 (en) * | 2008-04-23 | 2010-07-23 | Ignacio Umbert Millet | PERSONALIZED PHARMACEUTICAL COMPOSITION FOR THE REJUVENATION OF SKIN CONTAINING RETINOIC ACID. |
| US20100158842A1 (en) * | 2008-10-09 | 2010-06-24 | Spectrum Dynamics Llc | Natural skin whitener: 4-hydroxy-oxindole-3-acetic acid |
| FR2943542B1 (en) * | 2009-03-31 | 2012-05-25 | Lvmh Rech | METHOD OF ANTI-AGE COSMETIC CARE BY STIMULATING THE ACTIVITY OF MITOCHONDRIAL ACONISATE |
| FR2957801A1 (en) * | 2009-07-31 | 2011-09-30 | Georges Camprasse | Extracting active ingredients in mature Coco nucifera water, where the water is taken in a sterile manner by suction using a trocar connected to a peristaltic pump, introduced in one of germinal centers of the nut previously decontaminated |
| US8609075B2 (en) | 2009-09-30 | 2013-12-17 | Shiseido Company, Ltd. | Heparanase activity inhibitor |
| US8174881B2 (en) | 2009-11-24 | 2012-05-08 | Micron Technology, Inc. | Techniques for reducing disturbance in a semiconductor device |
| JP2011214909A (en) * | 2010-03-31 | 2011-10-27 | Daiichi Sankyo Healthcare Co Ltd | Method for detecting incorporation and transportation of melanosome by keratinocyte |
| CN103442691B (en) | 2010-09-10 | 2016-01-06 | 玫琳凯有限公司 | Comprise the topical skin care preparation of Myrciaria cauliflora and cashew nut tree sarcocarp and extract thereof |
| US9486400B2 (en) | 2012-06-18 | 2016-11-08 | The Proctor & Gamble Company | Method of improving the appearance of aging skin |
| MX359028B (en) * | 2012-08-30 | 2018-09-12 | Avon Prod Inc | Dickkopf-1 expression modulating compositions and uses thereof. |
| JP6375087B2 (en) * | 2013-03-04 | 2018-08-15 | 共栄化学工業株式会社 | Cosmetics |
| AU2014281486B2 (en) * | 2013-06-19 | 2017-03-30 | Elc Management Llc | Methods, compositions, and kit for whitening hyper pigmented spots on skin |
| CN108143668A (en) * | 2018-03-05 | 2018-06-12 | 无锡启集智能科技有限公司 | It is a kind of that there are skin care item for improving aging skin appearance and preparation method thereof |
| KR102118974B1 (en) * | 2018-09-20 | 2020-06-04 | 대봉엘에스 주식회사 | Coconut oil, and the uses thereof |
| WO2021260667A2 (en) | 2020-06-26 | 2021-12-30 | Universidade Do Minho | Composition for hair follicle modulation, methods and uses thereof |
| JP7458920B2 (en) * | 2020-07-07 | 2024-04-01 | 日華化学株式会社 | Hair cosmetics |
| CN118806866B (en) * | 2024-08-23 | 2025-04-18 | 广州中医药大学(广州中医药研究院) | A kind of perilla combined traditional Chinese medicine, effective component extraction method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5993835A (en) * | 1997-04-30 | 1999-11-30 | Mishima; Yutaka | Skin-whitening agent |
| US6551606B1 (en) * | 1999-06-10 | 2003-04-22 | Coty B.V. | Cosmetic product containing enzymes |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2041400A5 (en) * | 1969-04-23 | 1971-01-29 | Baudot Georges | Production of vegetable milks |
| US3671643A (en) * | 1969-09-15 | 1972-06-20 | Oreal | Treatment of excessive sebaceous glands secretion with substituted cysteamine compounds |
| US4372296A (en) * | 1980-11-26 | 1983-02-08 | Fahim Mostafa S | Treatment of acne and skin disorders and compositions therefor |
| JP2896815B2 (en) * | 1991-01-29 | 1999-05-31 | 有限会社野々川商事 | Cosmetics |
| KR930006432B1 (en) * | 1991-04-10 | 1993-07-16 | 주식회사 우방랜드 | Pharmaceutical compositions for treating acne |
| JPH0725742A (en) | 1993-07-15 | 1995-01-27 | Kao Corp | Whitening cosmetics |
| JP2952636B2 (en) * | 1993-12-27 | 1999-09-27 | 長瀬産業株式会社 | Melanin production inhibitor, method for producing the same, and whitening cosmetic containing the same |
| JP2884466B2 (en) | 1993-12-27 | 1999-04-19 | 長瀬産業株式会社 | Perilla extract, method for producing the same, and whitening cosmetic containing the same |
| JPH08291057A (en) * | 1995-02-22 | 1996-11-05 | Yuutoku Yakuhin Kogyo Kk | Cataplasm |
| AU716849B2 (en) * | 1995-06-23 | 2000-03-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Depigmenting activity of agouti signal protein and peptides thereof |
| CA2212314A1 (en) * | 1996-08-02 | 1998-02-02 | Institute For Advanced Skin Research Inc. | Composition for enhancing hyaluronic acid productivity and method for preparing same |
| JPH10265322A (en) | 1997-03-19 | 1998-10-06 | Shiseido Co Ltd | Skin preparation for external use |
| CN1235617C (en) * | 1998-03-31 | 2006-01-11 | 玫琳凯有限公司 | Skin lightening composition containing ascorbyl phosphate magnesium salt and UNINONTAN-U34TM (extract preparation of cucumber extract and lemon extract) |
| US5980904A (en) * | 1998-11-18 | 1999-11-09 | Amway Corporation | Skin whitening composition containing bearberry extract and a reducing agent |
| JP4015792B2 (en) | 1999-12-10 | 2007-11-28 | 株式会社コーセー | Whitening agent and external preparation for skin containing it as an active ingredient |
| JP2001181173A (en) | 1999-12-27 | 2001-07-03 | Kose Corp | Bleaching preparation for external use |
| CN1323577A (en) * | 2000-05-17 | 2001-11-28 | 刘晨 | Facial cleaning milk made of coconut milk |
| JP2002284663A (en) | 2001-03-27 | 2002-10-03 | Ichimaru Pharcos Co Ltd | Cosmetic composition |
| US20030129259A1 (en) * | 2001-12-28 | 2003-07-10 | Avon Products, Inc. | Topical lightening compostitions and methods of use |
| JP3803757B2 (en) | 2003-09-24 | 2006-08-02 | 独立行政法人物質・材料研究機構 | Ultrafine particle production equipment |
-
2001
- 2001-12-28 US US10/034,186 patent/US20030129259A1/en not_active Abandoned
-
2002
- 2002-11-06 CA CA002411222A patent/CA2411222C/en not_active Expired - Lifetime
- 2002-11-29 JP JP2002348249A patent/JP4601898B2/en not_active Expired - Fee Related
- 2002-12-02 MX MXPA02011912A patent/MXPA02011912A/en active IP Right Grant
- 2002-12-13 US US10/319,781 patent/US7014844B2/en not_active Expired - Fee Related
- 2002-12-19 EP EP02028448A patent/EP1325738B1/en not_active Expired - Lifetime
- 2002-12-19 DE DE60218125T patent/DE60218125T2/en not_active Expired - Lifetime
- 2002-12-20 PL PL357931A patent/PL211313B1/en not_active IP Right Cessation
- 2002-12-27 CN CNB021598061A patent/CN1293862C/en not_active Expired - Lifetime
-
2005
- 2005-08-31 US US11/215,874 patent/US7544351B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5993835A (en) * | 1997-04-30 | 1999-11-30 | Mishima; Yutaka | Skin-whitening agent |
| US6551606B1 (en) * | 1999-06-10 | 2003-04-22 | Coty B.V. | Cosmetic product containing enzymes |
Cited By (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11033491B2 (en) | 2002-10-25 | 2021-06-15 | Vyne Therapeutics Inc. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9539208B2 (en) | 2002-10-25 | 2017-01-10 | Foamix Pharmaceuticals Ltd. | Foam prepared from nanoemulsions and uses |
| US9320705B2 (en) | 2002-10-25 | 2016-04-26 | Foamix Pharmaceuticals Ltd. | Sensation modifying topical composition foam |
| US9622947B2 (en) | 2002-10-25 | 2017-04-18 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US9713643B2 (en) | 2002-10-25 | 2017-07-25 | Foamix Pharmaceuticals Ltd. | Foamable carriers |
| US9492412B2 (en) | 2002-10-25 | 2016-11-15 | Foamix Pharmaceuticals Ltd. | Penetrating pharmaceutical foam |
| US10821077B2 (en) | 2002-10-25 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US10322085B2 (en) | 2002-10-25 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US20120156144A1 (en) * | 2002-10-25 | 2012-06-21 | Foamix | Foamable Compositions, Kits and Methods for Hyperhidrosis |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US9636405B2 (en) | 2003-08-04 | 2017-05-02 | Foamix Pharmaceuticals Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US20060198809A1 (en) * | 2005-03-04 | 2006-09-07 | Woodridge Labs, Inc. | Gamma-amino butyric acid composition |
| US9682021B2 (en) | 2006-11-14 | 2017-06-20 | Foamix Pharmaceuticals Ltd. | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| US10369102B2 (en) | 2007-08-07 | 2019-08-06 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9662298B2 (en) | 2007-08-07 | 2017-05-30 | Foamix Pharmaceuticals Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US11103454B2 (en) | 2007-08-07 | 2021-08-31 | Vyne Therapeutics Inc. | Wax foamable vehicle and pharmaceutical compositions thereof |
| US9439857B2 (en) | 2007-11-30 | 2016-09-13 | Foamix Pharmaceuticals Ltd. | Foam containing benzoyl peroxide |
| US11433025B2 (en) | 2007-12-07 | 2022-09-06 | Vyne Therapeutics Inc. | Oil foamable carriers and formulations |
| US9795564B2 (en) | 2007-12-07 | 2017-10-24 | Foamix Pharmaceuticals Ltd. | Oil-based foamable carriers and formulations |
| US9161916B2 (en) | 2007-12-07 | 2015-10-20 | Foamix Pharmaceuticals Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| US9549898B2 (en) | 2007-12-07 | 2017-01-24 | Foamix Pharmaceuticals Ltd. | Oil and liquid silicone foamable carriers and formulations |
| US20100158829A1 (en) * | 2008-12-24 | 2010-06-24 | Conopco, Inc., D/B/A Unilever | Method and Composition for Color Modulation |
| US10588858B2 (en) | 2009-04-28 | 2020-03-17 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US9884017B2 (en) | 2009-04-28 | 2018-02-06 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10363216B2 (en) | 2009-04-28 | 2019-07-30 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US10213384B2 (en) | 2009-04-28 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof |
| US9572775B2 (en) | 2009-07-29 | 2017-02-21 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US9167813B2 (en) | 2009-07-29 | 2015-10-27 | Foamix Pharmaceuticals Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US11219631B2 (en) | 2009-07-29 | 2022-01-11 | Vyne Pharmaceuticals Inc. | Foamable compositions, breakable foams and their uses |
| US10092588B2 (en) | 2009-07-29 | 2018-10-09 | Foamix Pharmaceuticals Ltd. | Foamable compositions, breakable foams and their uses |
| US10350166B2 (en) | 2009-07-29 | 2019-07-16 | Foamix Pharmaceuticals Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| US10238746B2 (en) | 2009-10-02 | 2019-03-26 | Foamix Pharmaceuticals Ltd | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10967063B2 (en) | 2009-10-02 | 2021-04-06 | Vyne Therapeutics Inc. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| US10265404B2 (en) | 2009-10-02 | 2019-04-23 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US12138311B2 (en) | 2009-10-02 | 2024-11-12 | Journey Medical Corporation | Topical tetracycline compositions |
| US9675700B2 (en) | 2009-10-02 | 2017-06-13 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10463742B2 (en) | 2009-10-02 | 2019-11-05 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10517882B2 (en) | 2009-10-02 | 2019-12-31 | Foamix Pharmaceuticals Ltd. | Method for healing of an infected acne lesion without scarring |
| US10213512B2 (en) | 2009-10-02 | 2019-02-26 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10610599B2 (en) | 2009-10-02 | 2020-04-07 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10137200B2 (en) | 2009-10-02 | 2018-11-27 | Foamix Pharmaceuticals Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| US10821187B2 (en) | 2009-10-02 | 2020-11-03 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US10835613B2 (en) | 2009-10-02 | 2020-11-17 | Foamix Pharmaceuticals Ltd. | Compositions, gels and foams with rheology modulators and uses thereof |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| US10322186B2 (en) | 2009-10-02 | 2019-06-18 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10086080B2 (en) | 2009-10-02 | 2018-10-02 | Foamix Pharmaceuticals Ltd. | Topical tetracycline compositions |
| US10029013B2 (en) | 2009-10-02 | 2018-07-24 | Foamix Pharmaceuticals Ltd. | Surfactant-free, water-free formable composition and breakable foams and their uses |
| US9023327B2 (en) * | 2012-08-30 | 2015-05-05 | Avon Products, Inc. | DICKKOPF-1 expression modulating compositions and uses thereof |
| US11491225B2 (en) | 2014-12-23 | 2022-11-08 | Dyve Biosciences, Inc. | Transdermal carrier |
| US12070503B2 (en) | 2014-12-23 | 2024-08-27 | Dyve Biosciences, Inc. | Transdermal carrier |
| US10849847B2 (en) | 2016-09-08 | 2020-12-01 | Foamix Pharamaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US11324691B2 (en) | 2016-09-08 | 2022-05-10 | Journey Medical Corporation | Compositions and methods for treating rosacea and acne |
| US10398641B2 (en) | 2016-09-08 | 2019-09-03 | Foamix Pharmaceuticals Ltd. | Compositions and methods for treating rosacea and acne |
| US11357792B2 (en) | 2017-09-15 | 2022-06-14 | Dyvve Biosciences, Inc. | Method of administration and treatment |
| US11389472B2 (en) | 2017-09-15 | 2022-07-19 | Dyve Biosciences, Inc. | Method of administration and treatment |
| US11730756B2 (en) | 2017-09-15 | 2023-08-22 | Dyve Biosciences, Inc. | Method of administration and treatment |
| US11744853B2 (en) | 2017-09-15 | 2023-09-05 | Dyve Biosciences, Inc. | Method of administration and treatment |
| US11793830B2 (en) | 2017-09-15 | 2023-10-24 | Dyve Biosciences, Inc. | Method of administration and treatment |
| US12310983B2 (en) | 2017-09-15 | 2025-05-27 | Dyve Biosciences, Inc. | Method of administration and treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1325738A3 (en) | 2004-05-06 |
| US20050287089A1 (en) | 2005-12-29 |
| US7014844B2 (en) | 2006-03-21 |
| CN1494886A (en) | 2004-05-12 |
| PL211313B1 (en) | 2012-05-31 |
| JP2003212714A (en) | 2003-07-30 |
| EP1325738A2 (en) | 2003-07-09 |
| US7544351B2 (en) | 2009-06-09 |
| US20030157202A1 (en) | 2003-08-21 |
| CN1293862C (en) | 2007-01-10 |
| MXPA02011912A (en) | 2005-07-29 |
| CA2411222C (en) | 2010-01-19 |
| CA2411222A1 (en) | 2003-06-28 |
| DE60218125T2 (en) | 2007-11-22 |
| JP4601898B2 (en) | 2010-12-22 |
| EP1325738B1 (en) | 2007-02-14 |
| PL357931A1 (en) | 2003-06-30 |
| DE60218125D1 (en) | 2007-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7544351B2 (en) | Topical lightening compositions and methods of use | |
| US9089504B2 (en) | Cosmetic composition containing green tea component | |
| EP2168570A2 (en) | Extracts of isochrysis sp. | |
| US7862822B2 (en) | Extracts from black yeast for whitening skin | |
| US20160235646A1 (en) | A Topical Lightening Composition and Methods of Use Thereof | |
| CA2634924C (en) | Extracts from black yeast for whitening skin | |
| US20150342853A1 (en) | Topical Lightening Composition and Methods of Use Thereof | |
| EP3426017B1 (en) | Hydroponic tiliacora triandra and use thereof | |
| US9364405B2 (en) | Tyrosinase inhibitors | |
| KR101685554B1 (en) | Composition for improving skin containing callus of Broussonetia plant | |
| KR101781069B1 (en) | Composition for improving skin containing callus of Broussonetia plant | |
| KR101740373B1 (en) | Composition for improving skin containing callus of Broussonetia plant | |
| EP2260831A1 (en) | Plant extracts modulating Myo-X for use in compositions | |
| KR101131685B1 (en) | Cosmetic compositions having sebosuppressive effect | |
| JPH1029928A (en) | Skin preparation for external use | |
| US11523981B2 (en) | Cosmetic composition and its use, dermocosmetic formulation | |
| KR101781068B1 (en) | Composition for improving skin containing callus of Broussonetia plant | |
| US20150366787A1 (en) | Sesbania aculeata extracts and methods of use | |
| US20160235659A1 (en) | Antidesma bunius Extracts and Methods of Use | |
| KR20160150625A (en) | Composition for improving skin containing callus of Broussonetia plant | |
| HK1228825A1 (en) | Topical lightening composition and methods of use thereof | |
| WO2014158780A1 (en) | Phyllanthus acidus extracts and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: AVON PRODUCTS, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAHALINGAM, HARISH;JONES, BRIAN;MENON, GOPINATHAN K.;AND OTHERS;REEL/FRAME:012727/0675;SIGNING DATES FROM 20020305 TO 20020307 |
|
| AS | Assignment |
Owner name: AVON PRODUCTS, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAHALINGAM, HARISH;JONES, BRIAN;MENON, GOPINATHAN K.;AND OTHERS;REEL/FRAME:013942/0073;SIGNING DATES FROM 20030307 TO 20030317 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |